CJC-1295 + Ipamorelin Research Guide
What Is CJC-1295 & Ipamorelin?
CJC-1295 & Ipamorelin is a research blend that combines two widely studied compounds involved in growth hormone-related signalling pathways: CJC-1295, a Growth Hormone Releasing Hormone (GHRH) analogue, and Ipamorelin, a Growth Hormone Releasing Peptide (GHRP).
Due to their differing mechanisms of action, these compounds are frequently discussed together within peptide research. The combination has become one of the most recognised peptide blends within the growth hormone research category.
Researchers are often interested in studying how compounds that interact with separate signalling pathways may function within the same research model.
Understanding the Components
CJC-1295
CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). Researchers have investigated its interaction with GHRH receptors located within the anterior pituitary gland and its role within endocrine signalling pathways.
Ipamorelin
Ipamorelin is a synthetic Growth Hormone Releasing Peptide (GHRP). Unlike CJC-1295, it primarily interacts with the ghrelin receptor pathway and is often studied separately from GHRH analogues.
Because the two compounds belong to different peptide classes, they are frequently examined together within growth hormone-related research.
Why Researchers Study CJC-1295 & Ipamorelin
This peptide blend has been investigated across several scientific disciplines, including:
- Endocrine signalling
- Hormone-receptor interactions
- Growth hormone regulation
- Cellular communication pathways
- Peptide engineering
- Metabolic research
- Healthy ageing research
Its popularity within the peptide research community has resulted in a substantial body of scientific discussion and published literature.
What Makes This Combination Unique?
One of the distinguishing features of this blend is that it combines two compounds that interact with different biological signalling pathways.
CJC-1295
Acts through Growth Hormone Releasing Hormone (GHRH) receptors.
Ipamorelin
Acts primarily through the ghrelin receptor pathway.
Researchers have explored these pathways extensively due to their involvement in endocrine regulation and growth hormone signalling.
The combination of a GHRH analogue and a GHRP is one reason this blend remains a popular subject of investigation.
CJC-1295 & Ipamorelin Compared to Other Research Compounds
CJC-1295 & Ipamorelin
A research blend combining a GHRH analogue with a GHRP.
Tesamorelin
A synthetic GHRH analogue studied independently within growth hormone research.
CJC-1295 (No DAC)
A standalone GHRH analogue commonly referred to as Modified GRF 1-29.
CJC-1295 with DAC
A GHRH analogue incorporating a Drug Affinity Complex (DAC).
Growth Hormone Fragment 176-191
A synthetic peptide fragment frequently discussed within growth hormone-related research.
Each compound possesses a distinct structure and may be investigated for different scientific purposes.
Product Specifications
Compound: CJC-1295 & Ipamorelin
Contents: CJC-1295 + Ipamorelin
Quantity: 10mg Total Blend
Form: Lyophilised powder
Appearance: White to off-white powder
Storage: Store refrigerated upon receipt
Testing: Independently batch tested
Research Classification: Peptide Blend (GHRH Analogue + GHRP)
Independent Batch Testing
At Platinum Peptides, transparency and quality assurance remain central to our approach.
Every batch undergoes independent third-party analytical testing to verify identity and purity before being released.
Why Batch Testing Matters
Identity Verification
Confirms that the material matches the labelled compound.
Purity Analysis
Provides confidence that the sample meets established quality standards.
Consistency
Helps ensure batch-to-batch reliability and reproducibility.
Transparency
Allows researchers to review independent analytical data before making purchasing decisions.
Certificates of Analysis are available for each batch where applicable.
Storage Information
Lyophilised peptides should be stored in a cool, dry environment and protected from excessive heat, moisture and direct sunlight.
Researchers should always review appropriate storage conditions relevant to their specific protocols and applications.
Frequently Asked Questions
What is CJC-1295 & Ipamorelin?
CJC-1295 & Ipamorelin is a peptide blend containing a Growth Hormone Releasing Hormone (GHRH) analogue and a Growth Hormone Releasing Peptide (GHRP).
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 primarily interacts with GHRH receptors, while Ipamorelin primarily interacts with the ghrelin receptor pathway.
Is this a blended product?
Yes. This product contains both CJC-1295 and Ipamorelin within a single vial.
Why are CJC-1295 and Ipamorelin often discussed together?
Researchers frequently investigate compounds that interact with different growth hormone-related signalling pathways, making this a commonly referenced combination within peptide research.
Is CJC-1295 & Ipamorelin batch tested?
Yes. Platinum Peptides uses independent third-party testing to verify batch quality and purity.
How should CJC-1295 & Ipamorelin be stored?
Store in accordance with established peptide storage guidelines and maintain refrigeration where appropriate.
Related Research Compounds
Researchers interested in CJC-1295 & Ipamorelin may also wish to explore:
Important Information
This product is supplied strictly for laboratory research purposes only.
It is not intended for human consumption, therapeutic use, diagnostic use or veterinary use.
Researchers are responsible for ensuring compliance with all applicable laws, regulations and research protocols relating to the handling and use of peptide compounds.
Platinum Peptides does not provide guidance regarding dosage, administration, usage protocols or expected effects. Researchers are responsible for conducting their own independent research.